Harmony Biosciences Expands its CNS Pipeline Through the Acquisition of Epygenix Therapeutics
Shots:
- Harmony Biosciences has reported the acquisition of Epygenix Therapeutics to expand its late-stage CNS pipeline by adding rare epilepsy franchise
- The acquisition brings clemizole hydrochloride (EPX-100), under a registrational study for Dravet syndrome (topline data anticipated in 2026) and is scheduled to enter a P-III study for Lennox-Gastaut syndrome in H2’24, along with EPX-200, undergoing IND-enabling studies, into Harmony's pipeline
- Under the agreement, Epygenix received $35M in cash with a potential of receiving ~$130M as development & regulatory milestones plus additional ~$515M as sales-based milestones
Ref: Harmony Biosciences | Image: Harmony Biosciences
Related News:- Harmony Biosciences Collaborates with Bioprojet to Develop TPM-1116 as a Treatment of Narcolepsy and Other Sleep/Wake Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.